These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7418727)

  • 1. Chloroethylnorapomorphine, a proposed long-acting dopamine antagonist: interactions with dopamine receptors of mammalian forebrain in vitro.
    Baldessarini RJ; Kula NS; Arana GW; Neumeyer JL; Law SJ
    Eur J Pharmacol; 1980 Oct; 67(1):105-10. PubMed ID: 7418727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aporphines, 36. Dopamine receptor interactions of trihydroxyaporphines. Synthesis, radioreceptor binding, and striatal adenylate cyclase stimulation of 2,10,11-trihydroxyaporphines in comparison with other hydroxylated aporphines.
    Neumeyer JL; Arana GW; Law SJ; Lamont JS; Kula NS; Baldessarini RJ
    J Med Chem; 1981 Dec; 24(12):1440-5. PubMed ID: 7310821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aporphines. 30. (-)-N(2-chloroethyl)-10,11-dihydroxynor-aporphine (chloroethylnorapomorphine), a novel irreversible dopamine receptor antagonist.
    Neumeyer JL; Law SJ; Baldessarini RJ; Kula NS
    J Med Chem; 1980 Jun; 23(6):594-5. PubMed ID: 7392026
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible binding of [3H](-)N-chloroethylnorapomorphine to mammalian brain tissue.
    Baldessarini RJ; Kula NS
    Life Sci; 1983 Aug; 33(8):769-78. PubMed ID: 6193387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aporphines. 48. Enantioselectivity of (R)-(-)- and (S)-(+)-N-n-propylnorapomorphine on dopamine receptors.
    Neumeyer JL; Reischig D; Arana GW; Campbell A; Baldessarini RJ; Kula NS; Watling KJ
    J Med Chem; 1983 Apr; 26(4):516-21. PubMed ID: 6682147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of (-)N-(chloroethyl)-norapomorphine on [3H]-apomorphine binding to striatal dopamine receptors.
    Goosey MW; Doggett NS
    Biochem Pharmacol; 1982 Nov; 31(22):3693-4. PubMed ID: 7181954
    [No Abstract]   [Full Text] [Related]  

  • 7. Rigid analogues of dopamine: synthesis and interaction of 6-exo- and 6-endo-(3',4'-dihydroxyphenyl)-2-azabicyclo[2.2.2]octanes with dopamine uptake sites and receptors.
    Law SJ; Morgan JM; Masten LW; Borne RF; Arana GW; Kula NS; Baldessarini RJ
    J Med Chem; 1982 Mar; 25(3):213-6. PubMed ID: 7069700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-)- and (S)-(+)-2-hydroxyapomorphine.
    Neumeyer JL; Arana GW; Ram VJ; Kula NS; Baldessarini RJ
    J Med Chem; 1982 Aug; 25(8):990-2. PubMed ID: 7120288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The binding of [3H]N-(chloroethyl)-norapomorphine to rat striatal membranes.
    Kilpatrick GJ; Jenner P; Marsden CD
    Eur J Pharmacol; 1984 Dec; 107(1):71-8. PubMed ID: 6084599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.
    Fujita N; Nakahiro M; Fukuchi I; Saito K; Yoshida H
    Brain Res; 1985 May; 333(2):231-6. PubMed ID: 3158374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissociation of the striatal D-2 dopamine receptor from adenylyl cyclase following 6-hydroxydopamine-induced denervation.
    Thomas KL; Rose S; Jenner P; Marsden CD
    Biochem Pharmacol; 1992 Jul; 44(1):73-82. PubMed ID: 1321630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation between behavioral effects of (-)-N-(2-chloroethyl)-norapomorphine and D2 dopamine receptor-like activity.
    Helmeste DM
    Eur J Pharmacol; 1983 Nov; 95(3-4):277-81. PubMed ID: 6317413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aporphines as antagonists of dopamine D-1 receptors.
    Schaus JM; Titus RD; Foreman MM; Mason NR; Truex LL
    J Med Chem; 1990 Feb; 33(2):600-7. PubMed ID: 2405158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dopaminergic agonists and antagonists on [3H]apomorphine binding to striatal membranes: sulpiride lack of interactions with positive cooperative [3H]apomorphine binding.
    Fujita N; Saito K; Hirata A; Iwatsubo K; Noguchi Y; Yoshida H
    Brain Res; 1980 Oct; 199(2):335-42. PubMed ID: 7417787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the mechanism of mergocryptine-induced suppression of dopamine turnover in the rat striatum.
    Hashimoto T; Katsura M; Kuriyama K
    Eur J Pharmacol; 1991 Jun; 198(2-3):121-7. PubMed ID: 1864302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute reserpine treatment induces down regulation of D-1 dopamine receptor associated adenylyl cyclase activity in rat striatum.
    Thomas KL; Rose S; Jenner P; Marsden CD
    Biochem Pharmacol; 1992 Jul; 44(1):83-91. PubMed ID: 1321631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3H-Apomorphine interactions with dopamine receptors in calf brain.
    Thal L; Creese I; Snyder SH
    Eur J Pharmacol; 1978 Jun; 49(3):295-9. PubMed ID: 658143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine receptors modulating [3H]acetylcholine release in slices of the cat caudate: effects of (-)-N-(2-chloroethyl)-norapomorphine.
    Lehmann J; Lee CR; Langer SZ
    Eur J Pharmacol; 1983 Jun; 90(4):393-400. PubMed ID: 6884428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative activities of SCH 23390 and its analogs in three tests for D1/DA1 dopamine receptor antagonism.
    Barnett A; Ahn HS; Billard W; Gold EH; Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1986 Sep; 128(3):249-53. PubMed ID: 2878816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.